Adhesions may occur in up to 93% of patients following abdominopelvic laparotomy.1 SEPRAFILM can be used during both open hysterectomy and myomectomy to reduce adhesions and the complications they can cause.

SEPRAFILM and hysterectomy

In radical pelvic surgery, including hysterectomy, SEPRAFILM has been shown to reduce the extent of pelvic floor adhesions by 69% relative to historical controls.2

Learn more

Adhesions and myomectomy

Adhesions may occur in up to 93% of patients following abdominopelvic laparotomy.1

Learn more

SEPRAFILM efficacy

SEPRAFILM has been studied in more than 4000 patients and data have been published in 20 clinical reports.3,4

 

Review efficacy

What is SEPRAFILM?

Discover the science behind SEPRAFILM Adhesion Barrier in abdominopelvic surgery.

 

SEPRAFILM

Adhesive disease and your practice

Learn more about the incidence and severity of adhesions in abdominopelvic surgery.

Adhesive disease

Indication
Seprafilm® Adhesion Barrier is indicated for the reduction of post-surgical adhesions in patients undergoing abdominal or pelvic laparotomy.

Important Safety Information
Seprafilm should not be wrapped around an intestinal anastomosis as such usage may result in increased anastomotic leak related events, such as abscess or peritonitis. The safety and effectiveness of Seprafilm has not been established in combination with other adhesion prevention products and/or in surgical procedures not within the abdominopelvic cavity. The safety and effectiveness of Seprafilm has also not been evaluated in cases of pregnancy, malignancy, or frank infection. The type and frequency of adverse events reported are consistent with events typically seen following abdominopelvic surgery when used as directed.

Please see full prescribing information.

References:  1. Menzies D, Ellis H. Intestinal obstruction from adhesions—how big is the problem? Ann Royal Coll Surg Engl. 1990;72:60-63.  2. Bristow RE, Montz FJ. Prevention of adhesion formation after radical oophorectomy using a sodium hyaluronate-carboxymethylcellulose (HA-CMC) barrier. Gynecol Oncol. 2005;99:301-308. 3. Becker JM, Dayton MT, Fazio VW, et al. Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized, double-blind multicenter study. J Am Coll Surg. 1996;183:297-306. 4. Diamond MP. Reduction of adhesions after uterine myomectomy by Seprafilm membrane (HAL-F): a blinded, prospective, randomized, multicenter clinical study. Fertil Sterility. 1996;66:904-910.